Shield Therapeutics Plc · LSE:STX
Shield Therapeutics — Investor Presentation (September 2023)
23 slides from Shield Therapeutics's investor presentation, September 2023
Slide 1: Delivering on our Commercial Growth Strategy
Delivering on our Commercial Growth Strategy Corporate Presentation Corporate Presentation September 2023
Slide 2: Disclaimer
Disclaimer These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "pr
Slide 3: Key Highlights from Today's Announcements
Key Highlights from Today’s Announcements Announce H1 Financial Results Revenue and Other Income of US$8.6 million Accrufer US Product Sales of US$3.7 million SG&A Expenses of $17.7m Update on Q3 Prescription Demand and Market Access Expansion Record Prescription Demand accelerates in Q3 with foreca
Slide 4: The Unmet Needs of ID/IDA Patients are Real
The Unmet Needs of ID/IDA Patients are Real Up to 70% of people taking Up to 60% of patients will 70% traditional oral iron report 60% discontinue treatment due to gastrointestinal issues1,2 adverse reactions3 Isn’t it ironic -- What is meant to make patients feel better is making them feel worse 1.
Slide 5: Accrufer: Demonstrated Efficacy, Established Safety and Unprecedented Tolerability
Accrufer®: Demonstrated Efficacy, Established Safety and Unprecedented Tolerability Proprietary Accrufer® maltol formulation and unique MOA Data from three Phase 3 studies delivers a total of 60mg1 of elemental iron to the small demonstrated consistent efficacy intestine2 in both the IBD and CKD pop
Slide 6: Our Commercial Partnership Mission
OUR COMMERCIAL PARTNERSHIP MISSION To make Accrufer® the oral iron of choice in the U.S. 6
Slide 7: Shield is an Innovative Specialty Pharmaceutical Company; Strong Momentum Building
Strong Momentum Building Shield is an Innovative Specialty • 50% sequential increase in Q2 U.S. Accrufer® prescriptions Pharmaceutical Company • 80% increase* in Q3 U.S. Accrufer prescriptions Commercial Expansion with Viatris • Substantial acceleration of KPIs: 1st time writers, new completed in Ma
Slide 8: Financial Highlights for H1:2023
Financial Highlights for H1:2023 Revenues and Other Income of US$8.6M (H1:2022 - US$ 2.6M) • 118% increase of net product revenue from Accrufer® sales in US to US$3.7M (H1:2022 - US$1.7M) • Net average sales price for Accrufer® in US of US$119 in H1:2023 (H2: 2022 – US$124) • Other income of US$4.3M
Slide 9: A Significant Market, Ripe for Innovative Disruption
A Significant Market, Ripe for Innovative Disruption Estimated number of individuals with ~20 MILLION anemia in the U.S.* Large, defined market: 13.4M prescriptions per year, majority OTC iron Total available US market opportunity of US$2.3B** 80% of prescriptions written by Unsatisfied market drive
Slide 10: Exclusive, Multi-Year US Co-Commercial Agreement
Exclusive, Multi-Year US Co-Commercial Agreement Shared Vision to make Accrufer® market leader May-Jun 2023+ Launch of new 100- 100-person field sales team, 50 for person sales team Shield and 50 for Viatris targets 12,000 top HCPs & refreshed brand positioning Shield and Viatris split net revenue a
Slide 11: Expanded Sales Force Dramatically Increases Reach and Efficiency
Expanded Sales Force Dramatically Increases Reach and Efficiency Collectively calling on 12,000+ high prescribing HCP’s Enlarged Sales Force 100 sales reps and 12 core leaders, supported by a marketing, reimbursement and customer service with experience across all relevant indications Newly Launched
Slide 12: New Brand Campaign to Engage the Market – Launched May 2023
New Brand Campaign to Engage the Market – Launched May 2023 Introducing the “Ironic Campaign” 12
Slide 13: Strong Consecutive Quarterly Growth in Prescriptions, Following Commercial Expansion
Strong Consecutive Quarterly Growth in Prescriptions, Following Commercial Expansion 2023, Quarterly prescriptions 2022-2023, Quarterly prescriptions 28,454 +80% 15,808 +50% 10,476 9,249 Q/Q 7,317 5,794 Growth 2,820 1 1 1 1 1 1 2 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q1: 10,4761 Q2: 15,8081 Q3:
Slide 14: Substantial momentum - Sequential Q2 2023 KPI Increases
Substantial momentum- Sequential Q2 2023 KPI Increases Strong growth highlight early impact of expanded commercial team Key 2023 KPIs Average Monthly Prescription Growth May through August +26% First-Time Writers (Q2 vs Q1) +157% New Prescriptions (Q2 vs Q1) +63% Repeat Writers (Q2 vs Q1) +73% 14
Slide 15: Priorities to Drive Growth, Revenues & Improve Gross-To-Net
Priorities to Drive Growth, Revenues & Improve Gross-To-Net Improve Accelerate Expand Market Gross-to-Net Direct-to-Patient Access & Strategies Distribution 15
Slide 16: Accrufer available at two largest US Medicaid Programs
Accrufer® available at two largest US Medicaid Programs Total covered lives for Accrufer® now total 123MM New Medicaid Programs: 23MM Lives Commercial Plans and PBM’s: 16
Slide 17: Plans to Drive Systematic Improvement in Gross to Net
Plans to Drive Systematic Improvement in Gross to Net Increased in Prior Authorization (PA) Submissions and expanded Market Access Can Drive GTN Modify Patient New Field Access Team Expand Market Access Access Programs Adjust business rules for HCP to New, field based team (non-sales) with Focus on
Slide 18: Full Commercial Deployment Drives Accrufer Adoption
Full Commercial Deployment Drives Accrufer® Adoption Accrufer® market share targeting growth to 3.5-4%* by 2025 Estimated Annual Est. Net Revenue 3.5-4%* Prescriptions*: per Prescription*: Market Share* 2023 2023 2.5-3%* 100,000 – 130,000 Modest increase by Market Share* year-end 2023 2024 2024 Grea
Slide 19: Uses of Funds – Targeted Investment Areas
Uses of Funds – Targeted Investment Areas Commercial ~US$10M Investment Accelerate Initiatives to Improve Gross to Net Working Capital ~US$10M Investment Pre-Finance Build-up of Inventories & Receivables c Re-Payment of US$5.7M Shareholder Repayment of existing Loan Balance & Release Security over I
Slide 20: Potential for Significant Free Cash Flow
Potential for Significant Free Cash Flow US Net Product Revenue Potential of US$120M+ by 2025, assuming: More than 500,000 annual prescriptions in US with 100-person sales team Average US gross to net (GTN) discount approximately 60%, resulting in average net sales price of US$220-240 per prescripti
Slide 21: Global Partnerships Continue to Progress
Global Partnerships Continue to Progress Deals include upfronts, milestones & double-digit royalties United States EU+ 1 Canada Republic of Korea China + 2 Co-Commercial Sales volume increased License agreement Agreement for single PK Continuing enrolment Agreement, Dec. 2022 by 11% (H1:23 v H1:22)
Slide 22: A Rapidly Growing Business and Team That Can Execute
A Rapidly Growing Business and Team That Can Execute • Vast opportunity in US$2.3 billion* oral iron market as only FDA approved oral iron with broad label • Substantial and Accelerating Growth in Prescriptions • Accrufer® payer coverage increases to 123 million lives • Substantial acceleration of K
Slide 23: Thank You!
Thank You! Greg Madison – Chief Executive Officer Hans-Peter Rudolf – Chief Financial Officer
Shield Therapeutics — Investor Presentation (September 2023) on 6ix